FRONTLINE THERAPY OF CHRONIC MYELOID LEUKEMIA (CML)

被引：0
|
作者：
Kantarjian, Hagop [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
LEUKEMIA RESEARCH | 2014年 / 38卷
关键词：
D O I：
10.1016/S0145-2126(14)70007-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SP-001
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [41] Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China
    Cheng, Fang
    Yuan, Guolin
    Li, Qiang
    Cui, Zheng
    Li, Weiming
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [42] Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions
    Valent, Peter
    Gastl, Guenther
    Geissler, Klaus
    Greil, Richard
    Hantschel, Oliver
    Lang, Alois
    Linkesch, Werner
    Lion, Thomas
    Petzer, Andreas L.
    Pittermann, Elisabeth
    Pleyer, Lisa
    Thaler, Josef
    Wolf, Dominik
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 (03) : 370 - 377
  • [43] FISH studies of peripheral blood cells for monitoring therapy in chronic myeloid leukemia (CML).
    Tchirkov, A
    Briançon, G
    Giollant, M
    Travade, P
    Lacroute, G
    Ait-Ouaret, FA
    Shah, FA
    Malet, P
    AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (04) : A326 - A326
  • [44] Outcome after Discontinuation of Second Generation Tyrosine Kinase Inhibitors (TKIs) Used As Frontline Therapy for Patients (pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML)
    Abdelall, Waleed
    Kantarjian, Hagop M.
    Devendra, K. C.
    Akosile, Mary
    Borthakur, Gautam
    Verstovsek, Srdan
    Daver, Naval
    Pemmaraju, Naveen
    Naqvi, Kiran
    Garcia-Manero, Guillermo
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Ravandi, Farhad
    Konopleva, Marina
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [45] Clinical Significance of Dose Reductions of Dasatanib and Nilotinib When Used As Frontline Therapy for Chronic Phase -Chronic Myeloid Leukemia (CML-CP) Does Not Affect Outcome
    Malik, Asifa
    Kantarjian, Hagop M.
    Quintas-Cardama, Alfonso
    O'Brien, Susan
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Thomas, Deborah A.
    Burton, Elizabeth M.
    Jabbour, Elias
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1617 - 1618
  • [46] Questions Regarding Frontline Therapy of Acute Myeloid Leukemia
    Kantarjian, Hagop
    O'Brien, Susan
    CANCER, 2010, 116 (21) : 4896 - 4901
  • [47] EPIDEMIOLOGIC STUDIES OF CHRONIC MYELOID LEUKEMIA (CML) IN INDIA
    Levine, P. H.
    Hoffman, H.
    Mendizabal, A. M.
    Garcia-Gonzalez, V. Venkateshand P.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2011, 173 : S254 - S254
  • [48] Outcome prediction of chronic myeloid leukemia (CML) in children
    Leung, Wing-Yan
    Cheuk, Daniel Ka-Leung
    Cheng, Frankie Wai-Tsoi
    Leung, Alex Wing-Kwan
    Chiu, Ka-Ho
    Ho, Karin Kar-Huen
    Li, Chak-Ho
    Chan, Godfrey Chi-Fung
    ANNALS OF HEMATOLOGY, 2022, 101 (08) : 1677 - 1688
  • [49] SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
    Enrico, A.
    Pavlovsky, C.
    Mariano, R.
    Moiraghi, B.
    Bendek, G.
    Milone, J.
    HAEMATOLOGICA, 2013, 98 : 551 - 551
  • [50] Symptom Burden In Patients with Chronic Myeloid Leukemia (CML) on Kinase Inhibitor (KI) Therapy
    Williams, Loretta A.
    Garcia-Gonzalez, Araceli
    Ault, Patricia S.
    Williams, Janet L.
    Mobley, Gary M.
    Mendoza, Tito R.
    Cleeland, Charles S.
    Cortes, Jorge E.
    BLOOD, 2010, 116 (21) : 1570 - 1571
12345